Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxart, Inc.VXRT · Entity 6654 | Director | August 04, 2022 | August 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxart, Inc.
Report date August 04, 2022 · Filed August 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,217 |
Reported balance
After 2022-08-04 transaction · row 1
1 source rowRow 1 · 2022-08-04 · Grant · Acquired 6,217 · Balance 6,217 F1: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.91 · Expires 2032-08-03 | Direct | 37,280 |
Reported balance
After 2022-08-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-04 · Grant · Acquired 37,280 · Balance 37,280 F2: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant.
F2: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Elevation Oncology, Inc.
Report date July 23, 2025 · Filed July 24, 2025
Section 16 reporting ended · disclosed 2025-07-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.41 · Expires 2034-02-28 | Direct | 0 |
Reported balance
After 2025-07-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-23 · Disposition to issuer · Disposed 55,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2025-07-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-23 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.31 · Expires 2035-06-04 | Direct | 0 |
Reported balance
After 2025-07-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-23 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]
F3: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 23, 2024
Section 16 reporting ended · disclosed 2024-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,808 |
Reported balance
After 2024-01-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-23 · Disposition to issuer · Disposed 4,444 · Balance 6,808 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-01-23 · Disposition to issuer · Disposed 6,808 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-23 · Disposition to issuer · Disposed 7,520 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 23, 2025 Filed Jul 24, 2025 16:20 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001415889-25-020237 · form4-07242025_040702.xml · derivative · entry 3 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. Read SEC document |
| July 23, 2025 Filed Jul 24, 2025 16:20 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001415889-25-020237 · form4-07242025_040702.xml · derivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. Read SEC document |
| July 23, 2025 Filed Jul 24, 2025 16:20 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001415889-25-020237 · form4-07242025_040702.xml · derivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 8, 2025, by and among Elevation Oncology, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub VI, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On July 23, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.36 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). [continues to Footnote 2] F2 · derivative.exercise_date: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). As of immediately prior to and conditioned upon the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3] F3 · derivative.exercise_date: [continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding, it was cancelled for no consideration. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 16:10 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001415889-25-016223 · form4-06092025_040601.xml · derivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 16:19 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001415889-24-017188 · form4-06172024_080619.xml · derivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on the one-year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 16:28 UTC | Elevation Oncology, Inc. ELEV · Entity 77243 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001415889-24-006289 · form4-03042024_090338.xml · derivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The stock option vests as to 1/36th of the total shares monthly, beginning on March 29, 2024, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:38 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 7,520 | Not disclosed Strike: $45.66 | Not disclosed |
DisclosureSEC source: 0001140361-24-003536 · form4.xml · derivative · entry 3 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:38 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 6,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003536 · form4.xml · nonDerivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. Read SEC document |
| January 23, 2024 Filed Jan 23, 2024 20:38 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 4,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003536 · form4.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,808 F1 · security: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · security: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 18:22 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 6,808 | $58.75 | $399,970.00 |
DisclosureSEC source: 0001628280-24-000296 · wk-form4_1704324113.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,252 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 7,520 | $0.00 Strike: $45.66 | $0.00 |
DisclosureSEC source: 0001214659-23-001047 · marketforms-58258.xml · derivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 7,520 shares Expires 2033-01-20 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 16:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 4,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-001047 · marketforms-58258.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,444 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 18, 2023 Filed Jan 20, 2023 09:20 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 2,546 | $44.66 | $113,704.36 |
DisclosureSEC source: 0001214659-23-000876 · marketforms-58226.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2021. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:22 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 37,280 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001437749-22-019435 · rdgdoc.xml · derivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,280 Underlying: Common Stock · 37,280 shares Expires 2032-08-03 F2 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 22:22 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantCommon Stock | 6,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-019435 · rdgdoc.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,217 F1 · shares: Grant of shares upon vesting of restricted stock units. The shares underlying the award shall vest on the earlier of the date immediately prior of the 2023 annual meeting of stockholders of the Issuer and August 4, 2023, the first anniversary of the date of the grant. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 16:57 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,475 | $116.07 | $171,203.25 |
DisclosureSEC source: 0001214659-22-000947 · marketforms-55109.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,546 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 2, 2021. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 18:19 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 3,688 | $0.00 Strike: $124.31 | $0.00 |
DisclosureSEC source: 0001214659-22-000843 · marketforms-55079.xml · derivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688 Underlying: Common Stock · 3,688 shares Expires 2032-01-13 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 18:19 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-22-000843 · marketforms-55079.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,021 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 22:32 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 65,700 | $0.00 Strike: $8.34 | $0.00 |
DisclosureSEC source: 0001437749-21-020763 · rdgdoc.xml · derivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,700 Underlying: Common stock · 65,700 shares Expires 2031-08-19 F1 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of August 20, 2021, the date of the grantee's appointment as a director of Vaxart, Inc. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:25 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 10 | $203.00 | $2,030.00 |
DisclosureSEC source: 0001214659-21-002747 · marketforms-51753.xml · nonDerivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,475 Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 17:25 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,990 | $201.00 | $399,990.00 |
DisclosureSEC source: 0001214659-21-002747 · marketforms-51753.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,485 Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 18:15 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 2,155 | $0.00 Strike: $214.47 | $0.00 |
DisclosureSEC source: 0001214659-21-000676 · marketforms-50981.xml · derivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155 Underlying: Common Stock · 2,155 shares Expires 2031-01-14 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 18:15 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-000676 · marketforms-50981.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 20:30 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $113.20 | $0.00 |
DisclosureSEC source: 0001214659-20-000198 · marketforms-47240.xml · derivative · entry 2 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-01-02 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 20:30 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000198 · marketforms-47240.xml · nonDerivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 19:25 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $104.71 | $0.00 |
DisclosureSEC source: 0001190725-19-000022 · primary_doc.xml · derivative · entry 1 Cherrington Julie M · CIK 0001781315 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-26 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.